DAY ONE BIOPHARMACEUTICALS, INC.
395 Oyster Point Blvd., Suite 217
South San Francisco, CA 94080
June 8, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
| Attention: | Office of Life Sciences |
| Re: | Day One Biopharmaceuticals, Inc. |
Registration Statement on Form S-3
Filed June 1, 2022
File No. 333-265346
Via EDGAR - Acceleration Request
Requested Date: June 13, 2022
Requested Time: 9:00 a.m. Eastern Time
Ladies and Gentlemen:
Day One Biopharmaceuticals, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
| Sincerely, | ||
| DAY ONE BIOPHARMACEUTICALS, INC. | ||
| By: | /s/ Charles N. York II, M.B.A. | |
| Charles N. York II, M.B.A. | ||
| Chief Financial Officer | ||
| cc: | Jeremy Bender, Ph.D., M.B.A., Chief Executive Officer |
Charles N. York II, M.B.A., Chief Operating Officer
and Chief Financial Officer
Day One Biopharmaceuticals, Inc.
Robert A. Freedman, Esq.
Julia Forbess, Esq.
Fenwick & West LLP